Prescribed to treat anxiety and insomnia, benzodiazepines may do more than put the mind at ease. A new study links their prolonged use to increased Alzheimer’s risk.
Expansions in ataxin 2 predispose people to the ALS end of the ALS-FTD spectrum, and never cause pure FTD, according to a new French study.
When strict quality control standards are followed, low Aβ in cerebrospinal fluid accurately predicts amyloid plaques in people with cognitive impairment in clinical practice.
A new drug combination is better than standard therapy for congestive heart failure. It includes an inhibitor of neprilysin, a protease that digests Aβ in the brain.
Researchers in the United States, France, and Austria honored for pioneering work on deep-brain stimulation and L-dopa.
Moving beyond cell culture, neuroscientists are using CRISPR to tweak genes in living animals and perhaps, one day, as therapy in humans.
A hot new tool, CRISPR empowers researchers to slice, dice, and add their own spice to any gene. Neuroscientists are starting to reap the benefits.
The ALS Ice Bucket Challenge has yielded more than $100 million—what research projects should get a share of the action?
The Ice Bucket Challenge has poured more than $109 million into the coffers of ALS charities that support research. In one month alone it almost quadrupled the annual budget of the ALS Association. How will this money be spent? What types of study can and should be done now that were out of reach before? Experts weigh in with ideas while the charities formulate a plan.
This year's Lasker-DeBakey Clinical Medicine Research Award goes to Mahlon DeLong and Alim Louis Benabid for their pioneering work on deep-brain stimulation, which led to a therapy for more than 100,000 people with Parkinson's disease. The pair worked out how to override faulty motor circuitry that causes tremors. They will share $250,000, to be awarded in New York on September 19.
Add, delete, edit, repeat. With CRISPR, a hot new genome-editing technique, the sky seems to be the limit on what researchers can do to the genome. Harnessing a tool once wielded only by bacteria, researchers are using CRISPR to make transgenic animals, correct disease-causing mutations, add therapeutic genes to stem cells, and perhaps one day, some suggest, treat genetic disease in humans. Neuroscientists are now getting in on the act, and the first CRISPR-modified neurons have just been reported. More applications for neurodegenerative disease are on the horizon, as researchers move forward with the tool and work out its kinks. This two-part series explores the rise of CRISPR, how neuroscientists are putting it to use, and the challenges and possibilities that lie ahead.
- Bengt Winblad on Benzodiazepine use and risk of Alzheimer's disease: case-control study.
- Rebecca Gottesman on Angiotensin-neprilysin inhibition versus enalapril in heart failure.
- Nikolaos K. Robakis on Evidence for lymphatic Aβ clearance in Alzheimer's transgenic mice.
- Thomas Wisniewski on Evidence for lymphatic Aβ clearance in Alzheimer's transgenic mice.
- Xinglong Wang on Mislocalized Mitochondria Sufficient for Motor Neuron Malaise
- Carlos Cruchaga on Genetic variability in the regulation of gene expression in ten regions of the human brain.
- Philip De Jager on Genetic variability in the regulation of gene expression in ten regions of the human brain.